Prosper Junior Bakiny has positions in Eli Lilly and Viking Therapeutics. The Motley Fool recommends Viking Therapeutics. The ...

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic. Click here for ...

The artificial-intelligence trade may be one of the prevailing narratives in the stock market right now, but it turns out one ...

The stock makes the Nasdaq top gainers list today following news on the close yesterday. Genprex is trading at 0.7695, up ...

List today: Adherex Technologies FENC is a clinical-stage biotechnology company which is focused on the development of Sodium ...

A rebound in global biotech deals this year looks set to accelerate as big pharmaceutical companies seek new sources of ...

As of October 2025, the U.S. stock market has been experiencing significant volatility, with major indices like the Nasdaq and S&P 500 rebounding sharply after recent declines due to geopolitical ...

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and ...

Shares of companies such as Divi's Laboratories, Syngene, Laurus Labs, Piramal Pharma and Blue Jet Healthcare surged up to 5% ...

Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market.

After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus.